BoltzMol-1 finds hits on WRN target that resisted 350,000 screened compounds
GabriCorso · x · 2026-09-16
Boltz published a real-world hit discovery case study for BoltzMol-1, targeting Werner helicase (WRN) — a synthetic-lethal dependency in MSI-H tumors common in colorectal, gastrointestinal and endometrial cancers.
Key points:
- WRN is an attractive test case: MSI-H tumor cells are 'addicted' to WRN for resolving stalled replication structures, so inhibiting it kills them while healthy cells tolerate its loss.
- The study asks whether the new model can surface novel chemical starting points on real drug-discovery targets with modest compute budgets and short timelines, rather than just recovering known binding modes.
- Benchmark comparison: Novartis needed three screening campaigns covering nearly 350,000 compounds to find its initial WRN hit — an effort the team estimates took months and cost at least an order of magnitude more.
- BoltzMol-1 is now available in Boltz Lab for researchers to run against their own targets.
Related event: BoltzMol-1 finds WRN inhibitors in ten days for under $10K(2 posts)→
More from Apps
- Non-designer credits vibe coding tool Paper with $20/month plan for transforming his design workflow — tushaarmehtaa · 2026-11-02
- AI slide builders keep overriding negative prompts: Gamma users hit hardcoded layout walls — waterySoup2344 · 2026-11-02
- User boards flight booked entirely by Grok Bot — XFreeze · 2026-11-02
- Motion Prompt: a 192-effect motion dictionary that makes AI nail your animations — aigclink · 2026-11-02
- Dev builds zero-subscription calorie tracker with Gemini BYOK, no backend needed — bonfiglioalessio · 2026-11-02
- Parents of 31-year-old Amazon engineer sue OpenAI after ChatGPT-guided medication taper led to her death — 新智元 · 2026-11-02